Q: What is Saphnelo used for?

Saphnelo is used to treat systemic lupus erythematosus .

Q: How does Saphnelo work?

Mechanism of Action Saphnelo (anifrolumab-fnia) is a monoclonal antibody, a type of protein designed to recognize and attach to specific structures in the body. It works by targeting the type I interferon receptor. In many people with systemic lupus erythematosus (SLE), the immune system is overactive due to high levels of proteins called type I interferons. These proteins act as messengers that signal the immune system to cause inflammation. While this response is helpful for fighting viruses, in lupus patients, it causes the body to attack its own healthy tissues. How It Targets Lupus Saphnelo helps manage lupus symptoms through the following process: Binding to receptors: The medication attaches to the type I interferon receptor located on the surface of various cells throughout the body. Blocking signals: By binding to these receptors, Saphnelo acts like a shield, preventing type I interferons from delivering their messages to the cells. Reducing immune activity: When these signals are blocked, the overactive immune response is dampened. This helps to reduce the chronic inflammation and tissue damage characteristic of lupus.

Q: What are the active ingredients in Saphnelo?

The active ingredient in Saphnelo is anifrolumab .

Q: What are the side effects of Saphnelo?

Common side effects of Saphnelo may include: upper respiratory tract infection nasopharyngitis infusion reactions Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Saphnelo and how do I take it?

How Saphnelo is Administered Saphnelo is given as an infusion into a vein (intravenous or IV). This procedure is performed by a healthcare professional in a clinical setting, such as a doctor's office, hospital, or infusion center. The infusion process generally takes about 30 minutes to complete. Frequency of Treatment This medication is usually scheduled once every four weeks. Your healthcare provider will determine the appropriate schedule for your treatment based on your medical condition and response to the therapy. Missed Doses If you miss an appointment for your Saphnelo infusion, contact your healthcare provider immediately to reschedule. It is important to receive your treatment as regularly as possible to maintain its effectiveness. Do not attempt to administer this medication yourself.

Q: Is Saphnelo safe during pregnancy and breastfeeding?

Pregnancy There is limited information regarding the use of Saphnelo in pregnant individuals. Because Saphnelo is a monoclonal antibody, it is likely to be transported across the placenta as a pregnancy progresses, particularly during the second and third trimesters. It is not yet known if the drug can cause fetal harm or affect reproductive capacity. Healthcare providers may encourage patients who become pregnant while receiving this medication to enroll in a pregnancy registry. These registries collect data to help researchers understand the effects of the drug on pregnancy outcomes and the health of the infant. Breastfeeding It is not known whether Saphnelo passes into human breast milk or if it has any effect on a nursing infant. When deciding whether to breastfeed while using this medication, it is important to consider the health benefits of breastfeeding alongside the clinical need for the drug and any potential risks to the child. Before starting Saphnelo, individuals should discuss their pregnancy status or plans for breastfeeding with their healthcare provider to evaluate the potential risks and benefits based on their specific situation.

Q: What forms and strengths does Saphnelo come in?

Available Forms Saphnelo is supplied as a concentrated liquid solution in a single-dose vial. It is administered exclusively as an intravenous (IV) infusion, which means it is delivered directly into a vein. Key characteristics of this medication form include: Administration: It must be prepared and given by a healthcare provider in a clinical setting. Preparation: The concentrated solution is diluted into an infusion bag before use. Single-use: Each vial is intended for a single dose only.

Q: What is the FDA approval status of Saphnelo?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved Saphnelo in July 2021. It is the first type I interferon receptor antagonist to receive regulatory approval for the treatment of lupus. Approved Indications Saphnelo is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Standard therapy typically includes medications such as corticosteroids, antimalarials, or immunosuppressants. Limitations of Use The FDA-approved labeling includes specific limitations for the use of this medication: Saphnelo has not been studied in patients with severe active lupus nephritis and is not recommended for this use. Saphnelo has not been studied in patients with severe active central nervous system lupus and is not recommended for this use. Safety and Regulatory Monitoring There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with Saphnelo. Regulatory authorities require monitoring for specific safety concerns, including: Serious Infections: Increased risk of respiratory infections and herpes zoster (shingles). Hypersensitivity: Risk of serious allergic reactions, including anaphylaxis. Malignancy: The potential risk for the development of cancers, which is a known consideration for many immunosuppressive therapies.

Question 1

What is Saphnelo?

Accepted Answer

Saphnelo is a type I interferon receptor antagonist. It is a monoclonal antibody that works by binding to specific subunits of the type I interferon receptor on the surface of cells.

By blocking these receptors, the medication limits the activity of type I interferons. These proteins are involved in the body's immune signaling and contribute to inflammation when they are overactive.

Question 2

What is Saphnelo used for?

Accepted Answer

Saphnelo is used to treat systemic lupus erythematosus.

Question 3

How does Saphnelo work?

Accepted Answer

Mechanism of Action

Saphnelo (anifrolumab-fnia) is a monoclonal antibody, a type of protein designed to recognize and attach to specific structures in the body. It works by targeting the type I interferon receptor.

In many people with systemic lupus erythematosus (SLE), the immune system is overactive due to high levels of proteins called type I interferons. These proteins act as messengers that signal the immune system to cause inflammation. While this response is helpful for fighting viruses, in lupus patients, it causes the body to attack its own healthy tissues.

How It Targets Lupus

Saphnelo helps manage lupus symptoms through the following process:

Binding to receptors: The medication attaches to the type I interferon receptor located on the surface of various cells throughout the body.
Blocking signals: By binding to these receptors, Saphnelo acts like a shield, preventing type I interferons from delivering their messages to the cells.
Reducing immune activity: When these signals are blocked, the overactive immune response is dampened. This helps to reduce the chronic inflammation and tissue damage characteristic of lupus.

Question 4

What are the active ingredients in Saphnelo?

Accepted Answer

The active ingredient in Saphnelo is anifrolumab.

Question 5

What are the side effects of Saphnelo?

Accepted Answer

Common side effects of Saphnelo may include:

upper respiratory tract infection
nasopharyngitis
infusion reactions

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Saphnelo?

Accepted Answer

Saphnelo belongs to the type I interferon receptor antagonist drug class.

Question 7

What is the dosage of Saphnelo and how do I take it?

Accepted Answer

How Saphnelo is Administered

Saphnelo is given as an infusion into a vein (intravenous or IV). This procedure is performed by a healthcare professional in a clinical setting, such as a doctor's office, hospital, or infusion center. The infusion process generally takes about 30 minutes to complete.

Frequency of Treatment

This medication is usually scheduled once every four weeks. Your healthcare provider will determine the appropriate schedule for your treatment based on your medical condition and response to the therapy.

Missed Doses

If you miss an appointment for your Saphnelo infusion, contact your healthcare provider immediately to reschedule. It is important to receive your treatment as regularly as possible to maintain its effectiveness. Do not attempt to administer this medication yourself.

Question 8

Is Saphnelo safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited information regarding the use of Saphnelo in pregnant individuals. Because Saphnelo is a monoclonal antibody, it is likely to be transported across the placenta as a pregnancy progresses, particularly during the second and third trimesters. It is not yet known if the drug can cause fetal harm or affect reproductive capacity.

Healthcare providers may encourage patients who become pregnant while receiving this medication to enroll in a pregnancy registry. These registries collect data to help researchers understand the effects of the drug on pregnancy outcomes and the health of the infant.

Breastfeeding

It is not known whether Saphnelo passes into human breast milk or if it has any effect on a nursing infant. When deciding whether to breastfeed while using this medication, it is important to consider the health benefits of breastfeeding alongside the clinical need for the drug and any potential risks to the child.

Before starting Saphnelo, individuals should discuss their pregnancy status or plans for breastfeeding with their healthcare provider to evaluate the potential risks and benefits based on their specific situation.

Question 9

What forms and strengths does Saphnelo come in?

Accepted Answer

Available Forms

Saphnelo is supplied as a concentrated liquid solution in a single-dose vial. It is administered exclusively as an intravenous (IV) infusion, which means it is delivered directly into a vein.

Key characteristics of this medication form include:

Administration: It must be prepared and given by a healthcare provider in a clinical setting.
Preparation: The concentrated solution is diluted into an infusion bag before use.
Single-use: Each vial is intended for a single dose only.

Question 10

What is the FDA approval status of Saphnelo?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Saphnelo in July 2021. It is the first type I interferon receptor antagonist to receive regulatory approval for the treatment of lupus.

Approved Indications

Saphnelo is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Standard therapy typically includes medications such as corticosteroids, antimalarials, or immunosuppressants.

Limitations of Use

The FDA-approved labeling includes specific limitations for the use of this medication:

Saphnelo has not been studied in patients with severe active lupus nephritis and is not recommended for this use.
Saphnelo has not been studied in patients with severe active central nervous system lupus and is not recommended for this use.

Safety and Regulatory Monitoring

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with Saphnelo. Regulatory authorities require monitoring for specific safety concerns, including:

Serious Infections: Increased risk of respiratory infections and herpes zoster (shingles).
Hypersensitivity: Risk of serious allergic reactions, including anaphylaxis.
Malignancy: The potential risk for the development of cancers, which is a known consideration for many immunosuppressive therapies.

Question 11

What should I know about Saphnelo and cost?

Accepted Answer

Factors Influencing Cost

Saphnelo is a specialty medication administered by a healthcare professional through an intravenous (IV) infusion. Because it is not a drug you purchase at a standard pharmacy, several factors determine the final cost:

Insurance Coverage: Most insurance plans, including Medicare and private insurance, provide coverage for Saphnelo. However, your specific plan will determine your out-of-pocket expenses, such as deductibles, copayments, or coinsurance.
Administration Fees: The total price includes the cost of the medication and the fees charged by the clinic or hospital for the infusion procedure and facility use.
Treatment Location: Costs may differ depending on whether you receive the infusion at a doctor's office, an independent infusion center, or a hospital outpatient department.

Financial Assistance Options

There are programs available that may help reduce the cost of Saphnelo for eligible patients:

Co-pay Programs: The manufacturer may offer a co-pay savings program for people with commercial insurance to help cover out-of-pocket costs.
Patient Assistance Programs: For those who are uninsured or underinsured, patient assistance programs may provide the medication at no cost or a significantly reduced rate based on financial need.

To understand your specific costs, it is recommended to contact your insurance provider and the healthcare facility where you will receive treatment for a detailed estimate.

Saphnelo

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Saphnelo

Hospitals.net Disclosure